Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,221 | 60 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $423.29 | 16 | $0 (2022) |
| PFIZER INC. | $369.66 | 9 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $272.34 | 4 | $0 (2020) |
| Amgen Inc. | $245.95 | 6 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $187.55 | 3 | $0 (2019) |
| UCB, Inc. | $176.09 | 3 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $113.45 | 4 | $0 (2018) |
| Celgene Corporation | $100.96 | 2 | $0 (2019) |
| Genentech, Inc. | $92.08 | 2 | $0 (2019) |
| Lilly USA, LLC | $79.99 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $19.01 | 1 | ABBVIE INC. ($19.01) |
| 2020 | $134.92 | 2 | E.R. Squibb & Sons, L.L.C. ($69.01) |
| 2019 | $617.14 | 9 | AbbVie, Inc. ($163.82) |
| 2018 | $525.89 | 21 | AbbVie, Inc. ($152.10) |
| 2017 | $924.37 | 27 | PFIZER INC. ($225.22) |
All Payment Transactions
60 individual payment records from CMS Open Payments — Page 3 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/05/2017 | Amgen Inc. | Prolia (Biological), Repatha | Food and Beverage | In-kind items and services | $26.85 | General |
| Category: Endocrinology | ||||||
| 04/13/2017 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $125.46 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 04/13/2017 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $10.60 | General |
| Category: Immunology | ||||||
| 04/07/2017 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: IMMUNOLOGY | ||||||
| 03/03/2017 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: DERMATOLOGY | ||||||
| 03/03/2017 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $4.91 | General |
| Category: Inflammation | ||||||
| 03/02/2017 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $62.25 | General |
| Category: Immunology | ||||||
| 02/23/2017 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $75.07 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 02/03/2017 | Celgene Corporation | Otezla (Drug) | Food and Beverage | In-kind items and services | $40.82 | General |
| Category: Dermatology | ||||||
| 01/13/2017 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $23.15 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 721 | 5,021 | $580,521 | $179,026 |
| 2022 | 5 | 629 | 5,024 | $528,926 | $164,547 |
| 2021 | 5 | 613 | 4,668 | $469,075 | $150,267 |
| 2020 | 8 | 878 | 4,366 | $430,202 | $131,458 |
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 343 | 764 | $278,096 | $75,229 | 27.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 38 | 3,780 | $164,700 | $67,444 | 40.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 186 | 265 | $65,455 | $19,260 | 29.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 114 | 114 | $63,156 | $15,837 | 25.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 40 | 98 | $9,114 | $1,255 | 13.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 322 | 735 | $259,455 | $71,288 | 27.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 38 | 3,900 | $173,280 | $66,958 | 38.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 175 | 246 | $59,040 | $17,529 | 29.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 54 | 54 | $29,052 | $7,635 | 26.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 40 | 89 | $8,099 | $1,137 | 14.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 333 | 707 | $242,501 | $71,897 | 29.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 34 | 3,600 | $151,200 | $59,332 | 39.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 196 | 260 | $60,580 | $16,168 | 26.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 13 | 13 | $6,786 | $1,765 | 26.0% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 37 | 88 | $8,008 | $1,104 | 13.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 31 | 3,240 | $136,080 | $50,051 | 36.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 253 | 356 | $117,124 | $30,359 | 25.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 313 | 439 | $98,775 | $25,635 | 26.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 119 | 119 | $59,500 | $16,024 | 26.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 72 | 75 | $6,150 | $4,389 | 71.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 33 | 36 | $4,284 | $3,243 | 75.7% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 35 | 79 | $7,189 | $995.21 | 13.8% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 22 | 22 | $1,100 | $762.06 | 69.3% |
About Dr. Todd Hofeling, M.D
Dr. Todd Hofeling, M.D is a Internal Medicine healthcare provider based in Santa Rosa, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/30/2007. The National Provider Identifier (NPI) number assigned to this provider is 1447451935.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Todd Hofeling, M.D has received a total of $2,221 in payments from pharmaceutical and medical device companies, with $19.01 received in 2022. These payments were reported across 60 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($2,221).
As a Medicare-enrolled provider, Hofeling has provided services to 2,841 Medicare beneficiaries, totaling 19,079 services with total Medicare billing of $625,297. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Rheumatology, Rheumatology
- Location Santa Rosa, CA
- Active Since 05/30/2007
- Last Updated 03/07/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1447451935
Products in Payments
- Humira (Biological) $342.59
- XELJANZ (Drug) $303.83
- ORENCIA (Biological) $272.34
- STELARA (Biological) $187.55
- Cimzia (Drug) $176.09
- Enbrel (Biological) $141.11
- COSENTYX (Biological) $113.45
- Otezla (Drug) $100.96
- EVENITY (Biological) $77.99
- BENLYSTA (Biological) $68.94
- Rituxan (Biological) $68.03
- TALTZ (Drug) $67.90
- Rinvoq (Biological) $61.69
- KEVZARA (Drug) $40.74
- Actemra (Biological) $38.77
- Prolia (Biological) $26.85
- UPTRAVI (Drug) $21.53
- RINVOQ (Biological) $19.01
- ACTHAR (Biological) $14.04
- FORTEO (Drug) $12.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Santa Rosa
Zeyad Kanaan, M.d, M.D
Internal Medicine — Payments: $230,599
Rajveer Sangera, Do, DO
Internal Medicine — Payments: $42,357
Pamela Maur, M.d, M.D
Internal Medicine — Payments: $41,731
Kent Matsuda, M.d, M.D
Internal Medicine — Payments: $9,102
Dr. Marlon Decastro, M.d, M.D
Internal Medicine — Payments: $7,445
Sara Keck, Md, MD
Internal Medicine — Payments: $7,051